Cetuximab treatment alters the content of extracellular vesicles released from tumor cells

References

• 1 Rokita M, Stec R, Bodnar L et al. Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. Onco Targets. Ther. 6, 967–976 (2013).
  MedlineGoogle Scholar
• 2 Galizia G, Lieto E, Orditura M et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J. Surg. 31(7), 1458–1468 (2007).
  MedlineGoogle Scholar
• 3 Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 7(4), 301–311 (2005).
  Medline CASGoogle Scholar
• 4 Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 269(44), 27595–27602 (1994).
  Medline CASGoogle Scholar
• 5 Peng D, Fan Z, Lu Y, Deblasio T, Scher H, Mendelsohn J. Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Up-Regulates p27 KIP1 and Induces G 1 Arrest in Prostatic Cancer Cell Line DU145 Advances in Brief Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Up-Regulates p27KIP1 and Induces (1996). http://cancerres.aacrjournals.org/content/56/16/3666.full.pdf.
  Google Scholar
• 6 Meira DD, Nóbrega I, de Almeida VH et al. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway. Eur. J. Cancer 45(7), 1265–1273 (2009).
  Medline CASGoogle Scholar
• 7 Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8), 1275–1280 (2007).
  Medline CASGoogle Scholar
• 8 Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120(4), 781–787 (2007).
  Medline CASGoogle Scholar
• 9 Huang S, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol. Cancer Ther. 1, 507–514 (2002).
  Medline CASGoogle Scholar
• 10 Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992–3995 (2006).
  Medline CASGoogle Scholar
• 11 Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer 15(3), 252–264 (2012).
  Medline CASGoogle Scholar
• 12 Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 279–286 (2005).
  Medline CASGoogle Scholar
• 13 Vader P, Breakefield XO, Wood MJA. Extracellular vesicles: emerging targets for cancer therapy. Trends Mol. Med. 20(7), 385–393 (2014).
  Medline CASGoogle Scholar
• 14 Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. Exosome Mediated Communication within the Tumor Microenvironment. Elsevier B.V. http://linkinghub.elsevier.com/retrieve/pii/S0168365915300018.
  Google Scholar
• 15 Vader P, Fens MH, Sachini N et al. Taxol^®-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor^® EL. Nanomedicine 8(7), 1127–1135 (2013).
  CASGoogle Scholar
• 16 Aung T, Chapuy B, Vogel D et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc. Natl Acad. Sci. USA 108(37), 15336–15341 (2011).
  Medline CASGoogle Scholar
• 17 Montermini L, Meehan B, Garnier D et al. Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content. J. Biol. Chem. 290(40), 24534–24546 (2015).
  Medline CASGoogle Scholar
• 18 Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl Acad. Sci. USA 106(10), 3794–9 (2009).
  MedlineGoogle Scholar
• 19 ImClone LLC. ERBITUX (Cetuximab). www.erbitux.com.
  Google Scholar
• 20 Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904–914 (2000).
  Medline CASGoogle Scholar
• 21 Liu B, Fan Z. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. Oncogene 20(28), 3726–3734 (2001).
  Medline CASGoogle Scholar
• 22 Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59(8), 1935–1940 (1999).
  Medline CASGoogle Scholar
• 23 Martin SJ, Reutelingsperger CP, McGahon AJ et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl–2 and Abl. J. Exp. Med. 182(5), 1545–1556 (1995).
  Medline CASGoogle Scholar
• 24 Erdbrügger U, Lannigan J. Analytical challenges of extracellular vesicle detection: a comparison of different techniques. Cytom. Part A doi:10.1002/cyto.a.22795 (2015) (Epub ahead of print).
  Google Scholar
• 25 Maas SLN, de Vrij J, van der Vlist EJ et al. Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics. J. Control. Release 200, 87–96 (2015).
  Medline CASGoogle Scholar
• 26 Gardiner C, Ferreira YJ, Dragovic RA, Redman CWG, Sargent IL. Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. J. Extracell. Vesicles doi:10.3402/jev.v2i0.19671 (2013).
  Google Scholar
• 27 Jaramillo ML, Leon Z, Grothe S, Paul-Roc B, Abulrob A, O'Connor McCourt M. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp. Cell Res. 312(15), 2778–2790 (2006).
  Medline CASGoogle Scholar
• 28 Ciravolo V, Huber V, Ghedini GC et al. Potential role of HER2–overexpressing exosomes in countering trastuzumab-based therapy. J. Cell. Physiol. 227(2), 658–667 (2012).
  Medline CASGoogle Scholar
• 29 Safaei R, Larson BJ, Cheng TC et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther. 4(10), 1595–1604 (2005).
  Medline CASGoogle Scholar
• 30 Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 63(15), 4331–4337 (2003).
  Medline CASGoogle Scholar
• 31 Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2(8), 569–579 (2002).
  Medline CASGoogle Scholar
• 32 Van Der Mijn JC, Sol N, Mellema W et al. Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. J. Extracell. Vesicles 3, 25657 (2014).
  MedlineGoogle Scholar
• 33 Ragusa M, Statello L, Maugeri M et al. Highly skewed distribution of miRNAs and proteins between colorectal cancer cells and their exosomes following Cetuximab treatment: biomolecular, genetic and translational implications. Oncoscience 1(2), 132–157 (2014).
  MedlineGoogle Scholar
• 34 Murayama Y, Shinomura Y, Oritani K et al. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J. Cell. Physiol. 216(1), 135–143 (2008).
  Medline CASGoogle Scholar
• 35 Khatua AK, Taylor HE, Hildreth JEK, Popik W. Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. J. Virol. 83(2), 512–521 (2009).
  Medline CASGoogle Scholar
• 36 Li J, Lee Y, Johansson HJ et al. Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles. J. Extracell. Vesicles 1, 1–12 (2015).
  CASGoogle Scholar
• 37 Liao H-J, Carpenter G. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res. 69(15), 6179–6183 (2009).
  Medline CASGoogle Scholar
• 38 Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 32(3–4), 623–642 (2013).
  Medline CASGoogle Scholar
• 39 Federici C, Petrucci F, Caimi S et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS ONE 9(2), e88193 (2014).
  MedlineGoogle Scholar